R&D Program LeadRallybioNew Haven, Connecticut, United States
OC 02.1 - Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
Saturday, June 24, 202313:00 – 13:15 ET